Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Trinity Biotech PLC changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 23 | 21 | −2 |
| Shares | 5.52M | 5.39M | −126.6K (−2.3%) |
| Value | $11.9M | $7.70M | −$4.21M (−35.3%) |
New holders (4)
Institutions that held Trinity Biotech PLC at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Envestnet Asset Management Inc | 110,901 | $159.0K | 0.00% |
| Whitefort Capital Management, LP | 35,068 | $50.0K | 0.04% |
| Susquehanna International Group, LLP | 22,799 | $33.0K | 0.00% |
| Simplex Trading, LLC | 7,498 | $10.0K | 0.00% |
Sold out (6)
Institutions that held Trinity Biotech PLC at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace, LLP | 34,703 | $75.0K |
| Navellier & Associates Inc | 15,485 | $33.0K |
| HRT Financial LP | 13,427 | $29.0K |
| Ground Swell Capital, LLC | 10,981 | $24.0K |
| Spire Wealth Management | 500 | $1.00K |
| JPMorgan Chase & Co | 2 | $0 |